ArticleJournal of dental sciences2025
Human umbilical cord mesenchymal stem cells secretome and nanoemulsion propolis combination ameliorate osteoclastogenesis in lipopolysaccharide-induced osteolysis in hyperglycemia rats.
Article in Journal of dental sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HUC-MSC secretome and Nanoemulsion Propolis synergistically modulate inflammatory responses in hyperglycemia-induced calvarial osteolysis.Journal of oral biology and craniofacial researchArticle
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Human umbilical cord mesenchymal stem cell secretome (HUCMSCS) and nanoemulsion propolis (NEP) from Tetragonula biroi may be beneficial regenerative medicine to reduce LPS-induced osteolysis with hyperglycemia. This study aimed to investigate the HUCMSCS and NEP effect on nuclear factor associated T-cell-1 (NFATc1), sclerostin, receptor activator kappa beta (RANK), its ligand (RANKL), the osteoprotegerin (OPG) expression, tartrate-resistant acid phosphatase (TRAPase), and cathepsin K (Ctsk) serum level in LPS-induced osteolysis in hyperglycemic Wistar rats ( Materials and methods: Twenty-eight healthy male Wistar rats, 1-2 months old and 250-300 g body weight, were divided into seven groups, namely K1: control group; K2: 100 μl LPS; K3: hyperglycemia (≥230 mg/dL); K4: 100 μl LPS with hyperglycemia; K5: LPS, hyperglycemia, and 100 μl NEP; K6: LPS, hyperglycemia, and 100 μl HUCMSCS; and K7: LPS, hyperglycemia, and 100 μl HUCMSCS and NEP. Results: Conclusion: HUCMSCS and NEP post-administration reduced osteoclastogenesis in LPS-induced osteolysis calvaria with hyperglycemic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.